United Therapeutics Corporation has appointed Victor Dzau to its Board of Directors, effective immediately. Dzau recently completed a 12-year term as President at the National Academy of Medicine and currently serves as Professor of Medicine and Director of the Mandel Center at Duke University, while also co-chairing the G20 High-Level Independent Panel on Financing Pandemic Preparedness and Response. Chairperson and CEO Martine Rothblatt stated that Dzau's experience in academic medicine, healthcare leadership, and global health policy would strengthen the company's strategic direction and long-term growth. Dzau commented that he looks forward to supporting United Therapeutics as it advances therapies for rare diseases and technologies to expand the availability of transplantable organs. Shares of United Therapeutics were trading up 0.73% at $533.40.
United Therapeutics CorporationAppointment of a board member with strong credentials, but no immediate operational or financial impact.